ANI Pharmaceuticals ANIP Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Revenues by Business | ||||||
| Generics and Other | $109.22M+5.5% | $103.49M+4.9% | $98.69M+4.7% | $94.21M-8.6% | $103.04M+23.1% | |
| Rare Disease and Brands | $128.24M-10.7% | $143.57M+11.2% | $129.13M+10.2% | $117.16M+24.5% | $94.08M-12.0% | |
| Other (expense)income , net by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | ||||||
| Generics and Other | $40.32M+21.5% | $33.19M-5.4% | $35.08M-8.1% | $38.18M-21.4% | $48.54M+99.1% | |
| Rare Disease and Brands | $36.25M-26.0% | $48.99M+17.6% | $41.66M+41.4% | $29.46M+39.4% | $21.13M-26.2% | |
| Operating Income (Loss) by Business | ||||||
| Generics and Other | $40.32M+21.5% | $33.19M-5.4% | $35.08M-8.1% | $38.18M-21.4% | $48.54M+99.1% | |
| Rare Disease and Brands | $36.25M-26.0% | $48.99M+17.6% | $41.66M+41.4% | $29.46M+39.4% | $21.13M-26.2% | |
| Net Interest Expense by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Cost of sales (excluding depreciation and amortization) by Business | ||||||
| Generics and Other | $59.59M+1.9% | $58.49M+8.8% | $53.74M+24.3% | $43.23M-7.0% | $46.5M-1.0% | |
| Rare Disease and Brands | $33.99M-18.6% | $41.78M+5.4% | $39.65M+26.3% | $31.38M+18.3% | $26.54M-20.3% | |
| Selling, General and Administrative Expense by Business | ||||||
| Generics and Other | $1.52M+3.3% | $1.47M+4.8% | $1.41M+1.2% | $1.39M-1.3% | $1.41M+1.8% | |
| Rare Disease and Brands | $55.19M+8.5% | $50.88M+15.7% | $43.98M-14.1% | $51.19M+20.6% | $42.44M+8.1% | |
| Unrealized gain (loss) on investment in equity securities by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Research and Development expense by Business | ||||||
| Generics and Other | $7.79M-24.7% | $10.34M+22.1% | $8.47M-25.8% | $11.41M+73.3% | $6.59M-39.8% | |
| Rare Disease and Brands | $2.81M+46.4% | $1.92M-49.9% | $3.83M-25.2% | $5.12M+28.8% | $3.98M-30.2% | |
| D&A by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Contingent consideration fair value adjustment by Business | ||||||
| Generics and Other | $0— | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | $0— | |
| Net Revenues by Product | ||||||
| Brand royalties and other revenues | $21.54M— | —— | —— | —— | $0— | |
| Brands | $12.33M+0.1% | $12.32M+15.4% | $10.68M-19.1% | $13.2M-47.5% | $25.12M+26.6% | |
| Cortrophin Gel | $75.12M-32.6% | $111.43M+9.4% | $101.85M+24.7% | $81.65M+54.5% | $52.85M-11.0% | |
| Generic pharmaceutical products | $105.4M+4.6% | $100.76M+6.8% | $94.38M+4.5% | $90.3M-8.5% | $98.68M+25.5% | |
| ILUVIEN and YUTIQ | $19.26M-3.0% | $19.84M+19.5% | $16.6M-25.6% | $22.32M+38.5% | $16.11M-41.7% | |
| Other generic revenues | $3.82M— | —— | —— | —— | $4.36M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ANI Pharmaceuticals break its business down?
- ANI Pharmaceuticals (ANIP) reports net revenues by business across 2 parts — Generics and Other and Rare Disease and Brands. Each is extracted from the segment footnotes and tracked over time.
- Where does ANI Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ANI Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
